PROGRAM

ALMA MATER STUDIORUM
UNIVERSITÀ DI BOLOGNA
DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE

POLICLINICO DI
SANT'ORSOLA

SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Azienda Ospedaliero - Universitaria di Bologna

New Drugs in Hematology



President: Pier Luigi Zinzani

Co-President: Michele Cavo

Honorary President: Sante Tura

Bologna,
Royal Hotel Carlton
October 1-3, 2018

BOLOGNA

BOLOGNA, ROYAL HOTEL CARLTON

Auspices

ALMA MATER STUDIORUM
UNIVERSITÀ DEGLI STUDI DI BOLOGNA

REGIONE EMILIA-ROMAGNA

AZIENDA OSPEDALIERO-UNIVERSITARIA
DI BOLOGNA

AIL ASSOCIAZIONE ITALIANA CONTRO
LE LEUCEMIE - LINFOMI E MIELOMA
SEZIONE DI BOLOGNA

SIE - SOCIETÀ ITALIANA DI EMATOLOGIA

FACULTY

Ranjana H.	**Advani**	Stanford, USA
Stephen M.	**Ansell**	Rochester, USA
Andrea	**Artoni**	Milan, Italy
Michele	**Baccarani**	Bologna, Italy
Andrea	**Bacigalupo**	Rome, Italy
Nizar J.	**Bahlis**	Calgary, Canada
Ivan M.	**Borrello**	Baltimore, USA
Massimo	**Breccia**	Rome, Italy
Lars	**Bullinger**	Berlin, Germany
Christian	**Buske**	Ulm, Germany
John	**Byrd**	Columbus, USA
Michele	**Cavo**	Bologna, Italy
Robert	**Chen**	Duarte, USA
Bruce D.	**Cheson**	Washington, USA
Paolo	**Corradini**	Milan, Italy
Jorge E.	**Cortes**	Houston, USA
Antonio	**Cuneo**	Ferrara, Italy
Ian W.	**Flinn**	Nashville, USA
Robin	**Foà**	Rome, Italy
Andres	**Forero-Torres**	Birmingham, USA
Nathan H.	**Fowler**	Houston, USA
Francesco	**Galimi**	Thousand Oaks, USA
Leo I	**Gordon**	Chicago, USA
Claire	**Harrison**	London, United Kingdom
Elias	**Jabbour**	Houston, USA
Joseph G.	**Jurcic**	New York, USA
Wojciech J.	**Jurczak**	Kraków, Poland
Jean-Jacques	**Kiladjian**	Paris, France
Arne	**Kolstad**	Oslo, Norway
Marina Y.	**Konopleva**	Houston, USA
Shaji K.	**Kumar**	Rochester, USA
John	**Kuruvilla**	Toronto, Canada
Mark	**Levis**	Baltimore, USA
Giovanni	**Martinelli**	Meldola-FC, Italy
John O.	**Mascarenhas**	New York, USA
Anthony R.	**Mato**	New York, USA
Philippe	**Moreau**	Nantes, France
Alison J.	**Moskowitz**	New York, USA
Craig H.	**Moskowitz**	Miami, USA
Sattva S.	**Neelapu**	Houston, USA
Susan M.	**O'Brien**	Irvine, USA
Owen A.	**O'Connor**	New York, USA
Michinori	**Ogura**	Kasugai City, Japan
Cristina	**Papayannidis**	Bologna, Italy
Francesco	**Passamonti**	Varese, Italy
Carlos	**Paya**	Seattle, Usa
Ruth	**Pettengell**	London, United Kingdom
Vincent	**Ribrag**	Villejuif, France
Paul G.	**Richardson**	Boston, USA
Davide	**Rossi**	Bellinzona, Switzerland
Gianantonio	**Rosti**	Bologna, Italy
Simon A.	**Rule**	Plymouth, United Kingdom
Laurie H.	**Sehn**	Vancouver, Canada
John F.	**Seymour**	Melbourne, Australia
Michele	**Spina**	Aviano, Italy
Juan Louis	**Steegmann**	Madrid, Spain
Constantine	**Tam**	Melbourne, Australia
Alessandro M.	**Vannucchi**	Florence, Italy
Ravi	**Vij**	St. Louis, USA
Umberto	**Vitolo**	Turin, Italy
Anas	**Younes**	New York, USA
Andrew D.	**Zelenetz**	New York, USA
Pier Luigi	**Zinzani**	Bologna, Italy

Monday, October 1, 2018

9.00 a.m. *Welcome and Introduction*

Three recent "impressive" stories
Chairman: P. Corradini

9.15 a.m. Checkpoint inhibitors - *A. Younes*
9.40 a.m. Daratumumab - *M. Cavo*
10.05 a.m. CAR T-cells - *S.S. Neelapu*

SESSION I: Classical Ph1-neg myeloproliferative neoplasms
Chairmen: F. Passamonti, A.M. Vannucchi

10.45 a.m. Status of the art of treatment - *C. Harrison*
11.05 a.m. Ruxolitinib in myelofibrosis - *F. Passamonti*
11.20 a.m. Ruxolitinib in polycitemia vera - *A.M. Vannucchi*
11.35 a.m. Interferons in MPNs - *J.J. Kiladjian*
11.50 a.m. New drugs and combination therapy - *J.O. Mascarenhas*
12.05 p.m. Allotransplant in myelofibrosis - *A. Bacigalupo*

12.30 p.m. **Lunch**

SESSION II: Hodgkin's lymphoma
Chairmen: A. Younes, P.L. Zinzani

1.30 p.m. Status of the art of treatment - *A. Younes*
1.50 p.m. Nivolumab - *A. Younes*
2.05 p.m. Pembrolizumab - *R. Chen*
2.20 p.m. Brentuximab vedotin - *A.J. Moskowitz*
2.35 p.m. New Combo-steps - *S.M. Ansell*

Focus on: Prognostic factor and prediction of response in lymphoma
Chairman: B.D. Cheson

2.55 p.m. Can we use imaging to predict response? - *C.H. Moskowitz*
3.15 p.m. Role of circulating tumor DNA in response prediction and assessment of clonal evolution - *D. Rossi*

SESSION III: Acute leukemia
Chairmen: M. Levis, G. Martinelli

3.40 p.m. Status of the art: from genomic knowledge to target therapy in leukemias - *L. Bullinger*
4.00 p.m. Gliteritinib - *M. Levis*
4.15 p.m. Quizartinib - *J.E. Cortes*
4.30 p.m. SY-1425 - *J.G. Jurcic*
4.45 p.m. Inotuzumab in ALL - *E. Jabbour*
5.00 p.m. Venetoclax - *M.Y. Konopleva*
5.15 p.m. Idasanutlin - *C. Papayannidis*
5.30 p.m. Ponatinib - *E. Jabbour*
5.45 p.m. MCL1 inhibitors - *F. Galimi*
6.00 p.m. Blinatumumab in Ph+ and Ph neg ALL - *R. Foà*

SESSION IV: Non-Hodgkin's lymphoma (I)
Chairmen: S.M. Ansell, O.A. O'Connor

8.30 a.m. Status of the art of treatment - *S.M. Ansell*
8.50 a.m. Obinutuzumab - *L.H. Sehn*
9.05 a.m. MOR208 - *W.J. Jurczak*
9.15 a.m. Polatuzumab - *R.H. Advani*
9.30 a.m. Mogamulizumab - *M. Ogura*
9.45 a.m. CC-122 - *V. Ribrag*
10.00 a.m. EDO-S101 - *O.A. O'Connor*
10.15 a.m. Betalutin - *A. Kolstad*
10.30 a.m. Pixantrone - *R. Pettengell*

11.00 a.m. **Coffee break**

SESSION V: Chronic lymphocitic leukemia
Chairmen: A. Cuneo, R. Foà

11.15 a.m. Status of the art of management - *S.M. O'Brien*
11.35 a.m. Ibrutinib - *J. Byrd*
11.50 a.m. Idelalisib - *A.D. Zelenetz*
12.05 p.m. Venetoclax - *J. Seymour*
12.20 p.m. Acalabrutinib - *J. Byrd*
12.35 p.m. Zanubrutinib (BGB-3111) - *C. Tam*
12.50 p.m. Umbralisib (TGR-1202) - *A.R. Mato*

1.15 p.m. **Lunch**

Focus on: "The old, the new and the future in the same drug"
Chairman: M. Spina

2.15 p.m. Bendamustine - *B.D. Cheson*
2.35 p.m. Lenalidomide - *N.H. Fowler*
2.55 p.m. Rituximab biosimilars - *C. Buske*
3.15 p.m. Umbralisib (TGR-1202) - *A.R. Mato*

SESSION VI: Non-Hodgkin's lymphoma (II)
Chairmen: N.H. Fowler, U. Vitolo

3.50 p.m. Zanubrutinib (BGB-3111) - *C. Tam*
4.05 p.m. Venetoclax - *S.A. Rule*
4.20 p.m. Idelalisib - *S.M. Ansell*
4.35 p.m. Umbralisib - *O.A. O'Connor*
4.50 p.m. Copanlisib - *P.L. Zinzani*
5.05 p.m. Duvelisib - *I.W. Flinn*
5.20 p.m. INCB050465 - *A. Forero-Torres*
5.35 p.m. ME-401 - *A. Zelenetz*
5.50 p.m. Acalabrutinib - *S.A. Rule*
6.05 p.m. Tazemetostat - *V. Ribrag*
6.20 p.m. TAK-659 - *L.I. Gordon*
6.35 p.m. Selinexor - *J. Kuruvilla*

Lectures
Chairman: P.L. Zinzani

8.30 a.m. Thrombotic thrombocytopenic purpura: a look at the future - *A. Artoni*
8.50 a.m. G100 + Pembrolizumab - *C. Paya*

SESSION VII: Multiple myeloma
Chairmen: M. Cavo, P.G. Richardson

9.10 a.m. New proteasome inhibitors (Oprozomib, Marizomib) - *P.G. Richardson*
9.30 a.m. Selinexor - *N. Bahlis*
9.50 a.m. Venetoclax - *P. Moreau*
10.10 a.m. Monoclonal antibodies: Isatuximab, MOR202 - *S.K. Kumar*
10.30 a.m. Monoclonal antibodies and BTKs: anti-PD-1/PDL-1, Ibrutinib - *R. Vij*

SESSION VIII: Chronic myeloid leukemia
Chairman: G. Rosti

11.05 a.m. Bosutinib - *G. Rosti*
11.25 a.m. CAR-T and other immunotherapies - *I.M. Borrello*
11.40 a.m. Imatinib, nilotinib and dasatinib frontline: which and why? - *J.L. Steegmann*
11.55 a.m. ABI001 and combination - *M. Breccia*
12.10 p.m. Ponatinib - *M. Baccarani*
12.25 p.m. Treatment free remission - *G. Rosti*

12.45 p.m. Conclusions and Arrivederci

GENERAL INFORMATION

MEETING VENUE
Royal Hotel Carlton
Via Montebello, 8 - 40121 Bologna, Italy
Phone +39 051 249361 - Fax +39 051 249724
www.royalhotelcarltonbologna.com

OFFICIAL LANGUAGE
English

REGISTRATION FEE
Euro 400,00 (Italian VAT included)

The registration fee includes: conference kit, participation in the scientific sessions, attendance certificate, coffee breaks, lunches, slides of the meeting.

BADGE
All registered participants, speakers and sponsors will be given a badge which they must wear to be admitted to the scientific sessions.

CERTIFICATE OF ATTENDANCE
A certificate will be given to all participants at the end of the meeting.

ITALIAN CME CREDITS
An Italian CME application has been submitted as follows:

- Provider Studio ER Congressi SRL: ID 828-213626.
- No. **6 CME** credits for Physicians (disciplines: Allergology and Clinical Immunology, Dermatology and Venereology, Hematology, Oncology, Pathological Anatomy, Clinical Biochemistry, Clinical Pathology), Biologists and Chemists.
- Educational objective: “linee guida-protocolli-procedure”.

EUROPEAN CME CREDITS
The program of the “New Drugs in Hematology” has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH Unit has approved this educational activity for no. 22 CME credits for Physicians, Biologists and Chimists. To request credits, please fill out the form and return it to the registration desk at the end of the meeting. We remind you that it is necessary to have an EBAH-CME account in order to claim for credits. Attendees can create an EBAH-CME account registering on the website: http://ebah.org even on site.

CHANGES
Parts of the program may be changed without notice.

ACKNOWLEDGEMENTS

abbvie
Bristol-Myers Squibb
Celgene
GILEAD
janssen PHARMACEUTICAL COMPANIES OF Johnson & Johnson
Takeda
Acerta Pharma
AMGEN
HEALTHCARE CELLTRION
EDO
Incyte
MEI pharma
morphosys
mundipharma
NORDIC NANOVECTOR
NOVARTIS
Roche
SANDOZ A Novartis Division
SERVIER
TG Therapeutics
Verastem
BAYER
BeiGene
IMMUNE DESIGN
KYOWA KIRIN
Pfizer Oncology
SANOFI GENZYME

New Drugs in Hematology

Scientific Secretariat
Pier Luigi Zinzani
Istituto di Ematologia
"Lorenzo e Ariosto Seràgnoli"
Via Massarenti, 9 - 40138 Bologna, Italy
Phone +39 051 6363680 - Fax +39 051 6364037
E-mail: pierluigi.zinzani@unibo.it

Organizing Secretariat
Studio E.R. Congressi
Via Marconi, 36 - 40122 Bologna, Italy
Phone +39 051 4210559 - Fax +39 051 4210174
E-mail: ercongressi@ercongressi.it
www.ercongressi.it

struchel.com